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The glucuronic acid analogue of I-deoxynojirimycin, 2(5’)-carboxy-3(R), 4(R), Sag-~hydrox~i~~dine, 
recently isolated from seeds of Baphia racemosa, is a novel specific inhibitor of human liver #?-D-glucuroni- 
dase and a-L-iduronidase. No other glycosidases are inhibited. The inhibition of /?-D-glucuronidase is com- 
petitive, with a K, of 8 x lo+ M and is pH-deper&nt. This inhibitor may be useful to induce a mucopoly- 
saccharidosis or to investigate he function of microsomal ~-D-~ucoronida~. 
fl-D-Glucuroniakse a-L- Iduronike Novel glycosidase inhibitor Trihydroxypipecolic acid 
1. INTRODUCTION 
Naturally occurring inhibitors of glycosidases 
have been found to induce lysosomal storage 
phenomena [I] and to alter the processing of N- 
linked oligosaccharides of glycoproteins [2]. The 
bacterial piperidine nojirimycin and its derivatives, 
1-deoxynojirimycin and N-methyl-l-deoxynojiri- 
mycin [3-51 and the plant indoli~dine alkaloid, 
castanospermine [6] all alter the processing of N- 
linked glycans by inhibiting a-glucosidase I. o-D- 
mannosidase I and a-D-mannosidase II in the pro- 
cessing pathway are inhibited by the synthetic 
mannose analogue, .l-deox~~nojirimycin [7] 
and the plant indolizidine alkaloid, swainsonine, 
respectively [8,9]. Swainsonine also induces the ac- 
cumulation of partially hydrolysed and abnormal- 
ly processed oligosaccharides by completely in- 
hibiting Iysosomal ff-D-m~osid~e f 10, 11 J . 
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Fig.1. The structure of 2(~-c~boxy-3(~~, 4(R), S(S)- 
t~hydroxypi~ridine (BRl), e-L-iduronic acid and p-D- 
glucuronic acid. 
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been isolated from seeds of Baphia racemosa [121. 
We show that BRl inhibits human liver ,&D-glu- 
curonidase in vitro in a pH-dependent and com- 
petitive manner. The only other liver glycosidase 
inhibited is cr-L-iduronidase. 
2. MATERIALS AND METHODS 
2.1. Tissue 
Post-mortem human liver, which had been 
stored at - 20°C until required was homogenized 
(50070, w/v) in a Potter-Elvehjem homogenizer and 
then centrifuged at 37000 x g for 30 min in an 
MSE 18 centrifuge. The resultant supernatant was 
used as the source of enzymic activity. 
2.2. Inhibitor (BRI) 
2(s) - Carboxy - 3(R),4(R),5(S’) - trihydroxypiperi -
dine (BRl) was isolated from B. racemosa [12]. 
2.3. Glycosidase assays 
Glycosidases were assayed with the appropriate 
fluorigenic (4-methylumbelliferyl) substrate (Koch- 
Light, Haverhill, Suffolk) in the McIlvaine phos- 
phate-citrate buffer system as described previously 
[ 131. cu-L-iduronidase was assayed at pH 3.5 using 
0.5 mM 4-methylumbelliferyl cu-L-iduronide 
(Koch-Light) in 0.067 M sodium formate buffer. 
This substrate is known to be contaminated with 
4-methylumbelliferyl &B-D-glucuronide [ 141. As cy- 
L-iduronidase has negligible activity at pH 2.8 [14] 
it was possible to measure the amount of con- 
taminating ,&D-glucuronide by comparing the 
rates of hydrolysis by the liver extract at pH 2.8 of 
0.5 mM 4-methylumbelliferyl a-L-iduronide with 
a series of known concentrations of rl-methylum- 
belliferyl-B-D-glucuronide. The concentration of 
contaminating ,&6-D-glucuronide was found to be 
0.067 mM (approx. 14%). To assay the true a-L- 
iduronidase activity at pH 3.5 the rate of hydroly- 
sis at pH 3.5 of a control containing 0.067 mM 
4-methylumbelliferyl P-D-glucuronide was sub- 
tracted from the apparent a-L-iduronidase activi- 
ty. The effect of BRl on glycosidase activities was 
investigated by including 1O-5-1O-3 M BRl in the 
assay mixtures. The nature of the inhibition of ,& 
D-glucuronidase was determined by Lineweaver- 
Burk and Dixon graphical procedures, using a 
computer program to get the lines of best fit. One 
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unit of activity is a rate of 1 pmol of substrate 
hydrolysed per min. 
2.4. Measurement of pK 
The pK values of ionizing groups were measured 
by manual titration of a 50 mM solution of BRl 
with NaOH over the pH range 2-10 using a Kent 
Electronics 7060 pH meter. 
3. RESULTS AND DISCUSSION 
The only human liver glycosidases inhibited by 
BRl were ,&D-ghrcuronidase and a-L-iduronidase 
(table 1). Concentrations of BRl of 2.6 x lde4 M 
and 3.5 x 10e5 M produced 50% inhibition .of & 
D-glucuronidase and a-L-iduronidase respectively 
under the standard assay conditions. BRl is a com- 
petitive inhibitor of P-D-glucuronidase with a Ki 
value of 8 x 10m5 M at pH 4.75 (fig.2). The K,,, 
value for the substrate at this pH is 3.7 + 0.5 mM 
(mean f SD, n = 5). Rigorous kinetic studies could 
not be carried out on the effect of BRl on U-L- 
iduronidase because of the contamination of the 
substrate. However, limited studies indicated that 
the mode of inhibition was the same as for ,&D- 
glucuronidase. 
Table 1 
Inhibition of human liver glycosidases by BRl 
Glycosidase % Inhibitiona 
BRl 
1o-5 M 1o-3 M 
,&D-Glucuronidase 
(pH 4.75) 5 78 
cy-L-Iduronidase 
(PH 3.5) 20 96 
a-D-Glucosidase 0 7 
P-D-Glucosidase 
(pH 5.5) 0 2 
a-D)-Galactosidase 0 0 
,&D-Galactosidase 0 0 
cu-D-Mannosidase 0 3 
&B-D-Mannosidase 0 0 
P-D-N-Acetylglucosaminidase 0 0 
cY-L-Fucosidase 0 0 
a Expressed as the fraction of activity of control lost in 
presence of inhibitor. All assays at pH 4.0 with 
0.5 mM substrate unless otherwise indicated 
Volume 176, number 1 FRBS LETTERS October 1984 
The effect of pH on the inhibition of P-D- 
glucuronidase by BRl was inv~tigat~ (fig.3). It 
can be seen that the i~ibition is pH dependent, in- 
creasing with pH over the range pH 3.5-5.0. To 
ascertain whether this pH dependence was a reflec- 
tion of an ionization on the inhibitor, the titration 
curve of BRl was measured. Groups with pK 
values of 6.5 and approx. 2.5 were observed. It was 
assumed that these corresponded to the ionization 
of the ring N-atom and carboxyl group respective- 
ly. This suggests that BRl with an uncharged N- 
atom and an overall negative charge like the 
substrate is a more potent inhibitor. Conversely, 
the inhibition of m-D-mannosidase by swainsonine 
is greater at pH values below the pK (7.4) of the in- 
dolizidine ring nitrogen. It has been suggested that 
protonated swainsonine is a powerful competitive 
inhibitor (Ki 8 x lo-* M) because of its configura- 
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Fig.3. pH dependence of inhibition 
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presence of 0.25 mM BRl (0). The percentage 
in~bition by 0.25 mM BRl is shown at each pH value 
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Fig.2. ~n~bi~on of human liver ~-D-~ucuro~d~ by 
RR1 at pH 4.75. Different concentrations of BRl 
(1.0-5.0 x 10W4 M) were included in assay mixtures 
containing 1.67, 2.5 and 5 mM substrate. The nature of 
the inhibition and the value of Ki were determined 
graphically by the Dixon procedure. If fed to laboratory animals in large quantities 
It is interesting that BRl inhibits the cu-L- 
iduronide and the &B-D-glucuronide, which only 
differ in their configuration at C5. The ,&-D- 
glucoside, which has the s&me configuration as the 
~-D-glu~~onide for the ring substituents, i  not in- 
hibited by BRl, indicating the importance of the 
charged carboxyl in the binding or recognition 
mechanism. 
tional and conformations similarity to the man- 
nosy1 cation intermediate in the hydrolysis of man- 
nosides [15]. BRl may inhibit 8-D-glucuronidase 
by competing with the substrate rather than by be- 
ing a transition state analogue. The greater value 
of K; for BRl inhibition may reflect a difference in 
mechanism of inhibition of glycosidases by 
piperidine and indolizidine alkaloids. 
BRl is not as potent an inhibitor of ,&-3-r)- 
glucuronidase as D-g1ucaro-Alactam, which is 
prepared from nojirimycin by oxidation, or D- 
glucaro-l ,It-lactone [ 171. These latter compounds 
have Ki values of 4 x lo-* and 4.6 x 10e7 M, 
respectively, for the i~ibition of the hy~olysis of 
p-nitrophenyl &B-D-glucuronide by bovine liver ,&- 
glucuronidase. The conformation of the lactone 
and stable lactam probably resemble the half-chair 
conformation of the transition state. 
63 
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or administered tocells in culture, BRI may prove 
to be a useful corn~~d to induce a mucopolysac- 
charidosis and throw some light on the function of 
microsomal @-D-glucuronidase. 
ACKNOWLEDGEMENTS 
This work was supported by grants from the 
Medical Research Council and the Smith Kline 
Trust. P.D. was a Visiting Research Fellow at 
Queen Elizabeth College. The authors wish to 
thank Dr B. Schrire for the supply of B. mcemosa 
seeds. 
R.EFERENCES 
Ill 
121 
[31 
[41 
151 
Huxtable, C.R. and DorIing, P.R. (1982) Am. J. 
Pathol. 107, 124-126. 
Schwarz, R.T. and Datema, R. (1984) Trends 
Biochem. Sci. 9, 32-34. 
Saunier, B., Kilker, R.D., Tkacz, J.S., Quaroni, A, 
and Herscovics, A. (1982) J. Biol. Chem. 257, 
14155-14161. 
Peyrieras, N., Bause, E., Legler, G., VasiIov, R., 
Claesson, L., Peterson, P. and Ploegh, H. (1983) 
EMBO J. 2, 823-832. 
Romero, P.A., Datema, R. and Schwarz, R.T. 
(1983) Virology 130, 238-242. 
[6] Pan, Y.T., Hori, H., Saul, R., Sanford, B.A., 
Molynenx, R.J. and Elbein, A.D. (1983) 
Bio~he~st~ 22, 3975-3984, 
[7] Fuhrmann, U., Bause, E., Legler, G. and Ploegh, 
H. (1984) Nature 307, 755-758. 
181 Elbein, AD., Solf, R., Dorling, P.R. and Vosbeck, 
K. (1981) Proc. Natl. Acad. Sci. USA 78, 
7393-7397. 
191 Tulsiani, D.R.P., Harris, T.M. and Touster, 0. 
(1982) J. Biol. Chem. 257, 7936-7939. 
[lo] Abraham, D.J., Side~th~, R., Wi~ch~ter, B., 
Dorling, P.R. and DeII, A. (1983) FEBS Lett. 163, 
110-113. 
[ll] Cenci di BeIIo, I., Do&g, P. and Winchester, B. 
(1983) Biochem. J. 215, 693-696. 
[12] Manning, K.S., Lynn, D.G., Shabanowitz, J., 
Fellows, LE., Singh, M. and Schrire, B.D. (1984) 
J. Chem. Sot. Chem. Commun., in press. 
[13] Burditt, L.J., Chotai, K., Hiram, S., Nugent, P.G. 
and Winchester, B. (1980) Biochem. J. 189, 
467-473. 
[14] Hopwood, J.J., Muller, V., Smithson, A. and 
Baggett, N. (1979) Clin. Chim. Acta 92, 257-265. 
[15] Dorling, P.R., Huxtable, C.R. and Colegate, SM. 
(1980) Biochem. J. 191, 649-651. 
[16] Chotai, K., Jennings, C., Winchester, B. and 
Dorling, P. (1983) J. Cell Biochem. 21, 107-117. 
1171 Niwa, T., Tsuruoka, T., Inouye, S., Naito, Y., 
Koeda, T. and Niida, T. (1972) J. Biochem. 
(Tokyo) 72, 207-211. 
64 
